H-IMIGVLVGV-OH

Rif. 3D-PP48007

Informazioni sul prodotto

• Nome: H-IMIGVLVGV-OH

Descrizione

Peptide H-IMIGVLVGV-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-IMIGVLVGV-OH include the following: Assessment of cancer and virus antigens for cross-reactivity in human tissues V Jaravine, S Raffegerst, DJ Schendel - , 2017 - academic.oup.comhttps://academic.oup.com/bioinformatics/article-abstract/33/1/104/2525678 Targeting cancers through TCR-peptide/MHC interactions Q He, X Jiang, X Zhou, J Weng - Journal of hematology & oncology, 2019 - Springerhttps://link.springer.com/article/10.1186/s13045-019-0812-8 T-Cell Receptor-Transduced T Cells: Clinical Experience PF Robbins - The Cancer Journal, 2015 - journals.lww.comhttps://journals.lww.com/journalppo/FullText/2015/11000/T_Cell_Receptor_Transduced_T_Cells__Clinical.7.aspx On-and off target toxicity profiling for adoptive cell therapy by mass spectrometry-based immunopeptidome analysis of primary human normal tissues O Schoor, J Fritsche, S Kutscher, A Mahr - Cancer Research, 2016 - AACRhttps://aacrjournals.org/cancerres/article-abstract/76/14_Supplement/2291/609438 Characterization of genetically modified T-cell receptors that recognize the CEA: 691-699 peptide in the context of HLA-A2. 1 on human colorectal cancer cells MR Parkhurst, J Joo, JP Riley, Z Yu, Y Li - Clinical Cancer , 2009 - AACRhttps://aacrjournals.org/clincancerres/article-abstract/15/1/169/73405 Carcinoembryonic antigen (CEA)-based cancer vaccines: recent patents and antitumor effects from experimental models to clinical trials M Turriziani, M Fantini , M Benvenuto - Recent patents on , 2012 - ingentaconnect.comhttps://www.ingentaconnect.com/content/ben/pra/2012/00000007/00000003/art00004 Signaling via a CD28/CD40 chimeric costimulatory antigen receptor (CoStAR™), targeting folate receptor alpha, enhances T cell activity and augments tumor M Kalaitsidou, OR Moon, M Sykorova, L Bao - Frontiers in , 2023 - frontiersin.orghttps://www.frontiersin.org/articles/10.3389/fimmu.2023.1256491/full Carcinoembryonic antigen transgenic mouse models for immunotherapy and development of cancer vaccines M Bhattacharya-Chatterjee, A Saha - Current Protocols in , 2008 - Wiley Online Libraryhttps://currentprotocols.onlinelibrary.wiley.com/doi/abs/10.1002/0471142735.im2008s80 TAP-independent presentation of CTL epitopes by Trojan antigens J Lu, PJ Wettstein, Y Higashimoto - The Journal of , 2001 - journals.aai.orghttps://journals.aai.org/jimmunol/article/166/12/7063/33891 A novel transgenic mouse model for immunological evaluation of carcinoembryonic antigen-based DNA minigene vaccines H Zhou, Y Luo, M Mizutani, N Mizutani - The Journal of , 2004 - Am Soc Clin Investighttps://www.jci.org/articles/view/21107 Enhancing immunogenicity of a CTL epitope from carcinoembryonic antigen by selective amino acid replacements E Huarte , P Sarobe, J Lu, N Casares, JJ Lasarte - Clinical cancer , 2002 - AACRhttps://aacrjournals.org/clincancerres/article-abstract/8/7/2336/289158 Identification and validation of viral antigens sharing sequence and structural homology with tumor-associated antigens (TAAs). C Ragone, C Manolio, B Cavalluzzo - for ImmunoTherapy of , 2021 - ncbi.nlm.nih.govhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166618/

• Marchio: Biosynth